The closing price of Avidity Biosciences Inc (NASDAQ: RNA) was $24.09 for the day, down -4.97% from the previous closing price of $25.35. On the day, 798506 shares were traded.
Ratios:
Our analysis of RNA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.58 and its Current Ratio is at 7.58. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on March 14, 2024, initiated with a Overweight rating and assigned the stock a target price of $60.
On May 22, 2023, Evercore ISI Upgraded its rating to Outperform which previously was In-line but kept the price unchanged to $20.
Evercore ISI Downgraded its Outperform to In-line on March 31, 2023, while the target price for the stock was maintained at $20.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 03 ’24 when LEVIN ARTHUR A sold 20,000 shares for $27.11 per share. The transaction valued at 542,214 led to the insider holds 253,872 shares of the business.
Boyce Sarah sold 28,000 shares of RNA for $734,919 on Apr 02 ’24. The President and CEO now owns 112,117 shares after completing the transaction at $26.25 per share. On Mar 19 ’24, another insider, LEVIN ARTHUR A, who serves as the Director of the company, sold 5,000 shares for $23.97 each. As a result, the insider received 119,848 and left with 14,830 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 200.88 while its Price-to-Book (P/B) ratio in mrq is 3.81.
Stock Price History:
Over the past 52 weeks, RNA has reached a high of $27.66, while it has fallen to a 52-week low of $4.82.
Shares Statistics:
A total of 79.28M shares are outstanding, with a floating share count of 71.35M. Insiders hold about 10.49% of the company’s shares, while institutions hold 98.37% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by Moderna, Inc. analysts. The consensus estimate for the next quarter is $1.01, with high estimates of $289.58 and low estimates of $35.80.
EPS for the following year is $Stocks, with Stocks analysts recommending between $Stocks and $ETF.
